-
Low levels of serum 25-hydroxyvitamin D [25(OH)D] in non-institutionalized older adults were associated with future increased mortality from all causes and from cardiovascular disease.
-
Cholinesterase inhibitors place patients at risk for syncope, bradycardia, permanent pacemaker insertion, and hip fracture.
-
The antiplatelet effect of clopidogrel is dependent upon its conversion and activation through the 2C19 pathway of the P450 system. Blockade of this pathway occurs because of genetics, in persons who do not have sufficiently active 2C19, and pharmacotherapies that specifically block 2C19. Proton pump inhibitors (PPIs), particularly omeprazole, are recognized to be 2C19 inhibitors. Is there reason for concern?
-
The ECG shown above was obtained from a 72-year-old woman as a baseline. How would you interpret her ECG? How many blocked and early findings can you identify?
-
The FDA has approved the first treatment for relapsed or refractory peripheral T-cell lymphoma. Pralatrexate, an inhibitor of dihydrofolate reductase, was granted accelerated approval by the FDA. It will be marketed by Allos Therapeutics as Folotyn™.
-
Many clinical trials have confirmed the benefit of early invasive therapy for high-risk patients presenting with acute coronary syndromes (ACS). However, the optimal timing of cardiac catheterization in this group remains unknown.
-
This retrospective cohort study reaffirms the link between hyperglycemia and mortality in the ICU, but demonstrates that the risk does not apply equally to all patient groups and, instead, varies based on admission diagnosis.
-
Recombinant Panton-Valentine leukocidin (PVL) toxins showed lytic activity against human (but not murine) neutrophils. The lytic activity of culture supernatants of USA400 and USA300 strains of MRSA were completely neutralized by anti-PVL monoclonal antibodies. In contrast, phenol-soluble modulin alpha3 (PSM) failed to lyse human neutrophils but did enhance PVL-mediated neutrophil lysis.
-
Dabigatran etexilate is an oral compound that is converted after absorption by a serum esterase to dabigatran, a direct competitive inhibitor of thrombin.
-
Current indications for cardiac-resynchronization therapy (CRT) require that patients have New York Heart Association (NYHA) Class III or Class IV heart-failure symptoms.
